全文获取类型
收费全文 | 3479篇 |
免费 | 250篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 86篇 |
妇产科学 | 76篇 |
基础医学 | 348篇 |
口腔科学 | 148篇 |
临床医学 | 267篇 |
内科学 | 808篇 |
皮肤病学 | 62篇 |
神经病学 | 196篇 |
特种医学 | 210篇 |
外科学 | 691篇 |
综合类 | 36篇 |
一般理论 | 1篇 |
预防医学 | 203篇 |
眼科学 | 105篇 |
药学 | 195篇 |
中国医学 | 1篇 |
肿瘤学 | 312篇 |
出版年
2023年 | 26篇 |
2022年 | 18篇 |
2021年 | 82篇 |
2020年 | 55篇 |
2019年 | 74篇 |
2018年 | 103篇 |
2017年 | 71篇 |
2016年 | 59篇 |
2015年 | 89篇 |
2014年 | 119篇 |
2013年 | 133篇 |
2012年 | 209篇 |
2011年 | 230篇 |
2010年 | 118篇 |
2009年 | 134篇 |
2008年 | 200篇 |
2007年 | 195篇 |
2006年 | 194篇 |
2005年 | 181篇 |
2004年 | 159篇 |
2003年 | 166篇 |
2002年 | 152篇 |
2001年 | 68篇 |
2000年 | 72篇 |
1999年 | 51篇 |
1998年 | 38篇 |
1997年 | 30篇 |
1996年 | 31篇 |
1995年 | 26篇 |
1994年 | 42篇 |
1993年 | 17篇 |
1992年 | 64篇 |
1991年 | 53篇 |
1990年 | 47篇 |
1989年 | 43篇 |
1988年 | 27篇 |
1987年 | 22篇 |
1986年 | 37篇 |
1985年 | 28篇 |
1984年 | 32篇 |
1983年 | 34篇 |
1982年 | 17篇 |
1979年 | 19篇 |
1978年 | 15篇 |
1977年 | 18篇 |
1976年 | 12篇 |
1974年 | 19篇 |
1973年 | 11篇 |
1968年 | 12篇 |
1967年 | 14篇 |
排序方式: 共有3762条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Cristina Masini Maria Giuseppa Vitale Marco Maruzzo Giuseppe Procopio Ugo de Giorgi Sebastiano Buti Sabrina Rossetti Roberto Iacovelli Francesco Atzori Laura Cosmai Francesca Vignani Giuseppe Prati Sarah Scagliarini Annalisa Guida Annalisa Berselli Carmine Pinto 《Clinical genitourinary cancer》2019,17(1):e150-e155
Background
Pazopanib has been approved for first-line treatment of patients with metastatic renal-cell carcinoma on the basis of clinical trials that enrolled only patients with adequate renal function. Few data are available on the safety and efficacy of pazopanib in patients with renal insufficiency. This study investigated the effect of kidney function on treatment outcomes in such patients.Patients and Methods
We retrospectively analyzed data of metastatic renal-cell carcinoma patients treated with pazopanib from January 2010 to June 2016 with respect to renal function. Patients with Modification of Diet in Renal Disease ≤ 60 mL/min/1.73 m2 (group A) were compared to patients with Modification of Diet in Renal Disease > 60 mL/min/1.73 m2 (group B) in terms of progression-free survival, toxicities, response rates, and overall survival.Results
A total of 229 patients were included: 128 in group A and 101 in group B. Median progression-free survival was 14 months (95% confidence interval [CI], 9.4-18.5) and 17 months (95% CI, 11.4-22.8), and overall survival was 30.5 months (95% CI, 8-53) and 41.4 months (95% CI, 21-62) for group A and group B, respectively, with no significant difference (P = .6). No significant difference between the 2 groups was reported in the incidence of adverse events. Dose reductions were more frequent in group A patients (66% vs. 36%; P = .04).Conclusion
Although the dose of pazopanib was reduced more frequently in patients with renal impairment, kidney function at therapy initiation does not adversely affect the safety and efficacy of pazopanib. 相似文献6.
7.
8.
9.
Kimberly A. Lackey Ryan M. Pace Janet E. Williams Lars Bode Sharon M. Donovan Kirsi M. Jrvinen Antti E. Seppo Daniel J. Raiten Courtney L. Meehan Mark A. McGuire Michelle K. McGuire 《Maternal & child nutrition》2020,16(4)
The novel coronavirus SARS‐CoV‐2 has emerged as one of the most compelling and concerning public health challenges of our time. To address the myriad issues generated by this pandemic, an interdisciplinary breadth of research, clinical and public health communities has rapidly engaged to collectively find answers and solutions. One area of active inquiry is understanding the mode(s) of SARS‐CoV‐2 transmission. Although respiratory droplets are a known mechanism of transmission, other mechanisms are likely. Of particular importance to global health is the possibility of vertical transmission from infected mothers to infants through breastfeeding or consumption of human milk. However, there is limited published literature related to vertical transmission of any human coronaviruses (including SARS‐CoV‐2) via human milk and/or breastfeeding. Results of the literature search reported here (finalized on 17 April 2020) revealed a single study providing some evidence of vertical transmission of human coronavirus 229E; a single study evaluating presence of SARS‐CoV in human milk (it was negative); and no published data on MERS‐CoV and human milk. We identified 13 studies reporting human milk tested for SARS‐CoV‐2; one study (a non‐peer‐reviewed preprint) detected the virus in one milk sample, and another study detected SARS‐CoV‐2 specific IgG in milk. Importantly, none of the studies on coronaviruses and human milk report validation of their collection and analytical methods for use in human milk. These reports are evaluated here, and their implications related to the possibility of vertical transmission of coronaviruses (in particular, SARS‐CoV‐2) during breastfeeding are discussed. 相似文献
10.
Sumanta K. Pal MD Dean Bajorin MD Nazli Dizman MD Jean Hoffman-Censits MD David I. Quinn MD Daniel P. Petrylak MD Matthew D. Galsky MD Ulka Vaishampayan MD Ugo De Giorgi MD Sumati Gupta MD Howard A. Burris MD Harris S. Soifer PhD Gary Li PhD Hao Wang PhD Carl L. Dambkowski MD Susan Moran MD Siamak Daneshmand MD Jonathan E. Rosenberg MD 《Cancer》2020,126(11):2597-2606